Authorisation, one of the REACH processes for managing risks of substances of very high concern (SVHC), has the ultimate aim of phasing out SVHC of non-essential uses. In order to obtain an authorisation, companies must prove either that the risk to health and the environment is controlled or there are strong socio- economic arguments. After 5 years, it is important to draw some lessons from the efficiency of REACH, whilst at the same time reviewing the Risk Management part of the legislation.
Given the authorisation costs, how can industry still be competitive throughout the entire supply chain? What will be the impact on SMEs?
Is there a risk that authorization results in the allocation of critical parts of the value chain outside the EU, creating loss-loss situations for economics as well as environment & human health?
How does the authorisation fit into the critical raw materials directive? Will the authorisation process be taking into account other legislative directives such as resource and energy efficiency?
The Commission, supported by Member States and ECHA, will issue a roadmap on SVHC. How will RMO and stability to industry, and SMEs in particular, be taken into account?